Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ipsen SA
Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.
NICE says that Bavencio plus Inlyta will be made available via the Cancer Drugs Fund for advanced kidney cancer while more evidence is collected to support the combination therapy's routine use on the National Health Service.
Although Elonzris, the therapy at the heart of its recent acquisition of Stemline has just been rejected in Europe, Italy's Menarini is pushing on with its expansion in oncology and is paying $30m upfront to get the rights to Radius Health's Phase III hope elacestrant.
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Clementia Pharmaceuticals, Inc.
- Ipsen Bioscience, Inc.
- Tercica, Inc.
- Syntaxin Ltd.
- OctreoPharm Sciences GmbH
- Octagen Corporation